Maralixibat
Phase 3Completed 0 watching 0 views this week๐ Rising
74
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Progressive Familial Intrahepatic Cholestasis (PFIC)
Conditions
Progressive Familial Intrahepatic Cholestasis (PFIC)
Trial Timeline
Jul 9, 2019 โ Sep 1, 2022
NCT ID
NCT03905330About Maralixibat
Maralixibat is a phase 3 stage product being developed by Mirum Pharmaceuticals for Progressive Familial Intrahepatic Cholestasis (PFIC). The current trial status is completed. This product is registered under clinical trial identifier NCT03905330. Target conditions include Progressive Familial Intrahepatic Cholestasis (PFIC).
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04530994 | Pre-clinical | Completed |
| NCT07389031 | Phase 2 | Recruiting |
| NCT06553768 | Phase 3 | Recruiting |
| NCT04729751 | Phase 2 | Completed |
| NCT04524390 | Phase 2 | Completed |
| NCT04168385 | Phase 2 | Completed |
| NCT04185363 | Phase 3 | Completed |
| NCT03905330 | Phase 3 | Completed |
Competing Products
20 competing products in Progressive Familial Intrahepatic Cholestasis (PFIC)